|
1
|
Alektiar KM, Venkatraman E, Abu-Rustum N
and Barakat RR: Is endometrial carcinoma intrinsically more
aggressive in elderly patients? Cancer. 98:2368–2377. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kosary CL: FIGO stage, histology,
histologic grade, age and race as prognostic factors in determining
survival for cancers of the female gynecological system: An
analysis of 1973-87 SEER cases of cancers of the endometrium,
cervix, ovary, vulva, and vagina. Semin Surg Oncol. 10:31–46. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zaino RJ, Kurman RJ, Diana KL and Morrow
CP: Pathologic models to predict outcome for women with endometrial
adenocarcinoma: The importance of the distinction between surgical
stage and clinical stage-a Gynecologic Oncology Group study.
Cancer. 77:1115–1121. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abeler VM and Kjørstad KE: Endometrial
adenocarcinoma in Norway. A study of a total population. Cancer.
67:3093–3103. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Irwin C, Levin W, Fyles A, Pintilie M,
Manchul L and Kirkbride P: The role of adjuvant radiotherapy in
carcinoma of the endometrium-results in 550 patients with
pathologic stage I disease. Gynecol Oncol. 70:247–254. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saito T, Takahashi F and Katabuchi H: 2016
Committee on Gynecologic Oncology of the Japan Society of
Obstetrics and Gynecology: Annual Report of the Committee on
Gynecologic Oncology, Japan Society of Obstetrics and Gynecology:
Patient Annual Report for 2014 and Treatment Annual Report for
2009. J Obstet Gynaecol Res. 43:1667–1677. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carcangiu ML and Chambers JT: Early
pathologic stage clear cell carcinoma and uterine papillary serous
carcinoma of the endometrium: comparison of clinicopathologic
features and survival. Int J Gynecol Pathol. 14:30–38. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sakaki M, Yasuda M, Yano M, Goto Y,
Nakamura M, Kayano H and Hasegawa K: The prognostic significance of
tumor lymphangiogenesis and lymphatic vessel density in
endometrioid carcinoma of the uterine corpus. Oncol Lett.
14:5313–5318. 2017.PubMed/NCBI
|
|
9
|
Ogane N, Yasuda M, Kato H, Kato T, Yano M,
Kameda Y and Kamoshida S: Cleaved caspase-3 expression is a
potential prognostic factor for endometrial cancer with positive
peritoneal cytology. Cytopathology. 29:254–261. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carcangiu ML and Chambers JT: Uterine
papillary serous carcinoma: A study on 108 cases with emphasis on
the prognostic significance of associated endometrioid carcinoma,
absence of invasion, and concomitant ovarian carcinoma. Gynecol
Oncol. 47:298–305. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mutter GL and Prat J: Endometrial
adenocarcinoma. Pathology of the Female Reproductive Tract. 3rd
edition. Churchill Livingstone Elsevier; Boston, MA: pp.
3972014
|
|
12
|
Kounelis S, Kapranos N, Kouri E, Coppola
D, Papadaki H and Jones MW: Immunohistochemical profile of
endometrial adenocarcinoma: a study of 61 cases and review of the
literature. Mod Pathol. 13:379–388. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sherman ME, Bur ME and Kurman RJ: p53 in
endometrial cancer and its putative precursors: Evidence for
diverse pathways of tumorigenesis. Hum Pathol. 26:1268–1274. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lax SF, Kendall B, Tashiro H, Slebos RJ
and Hedrick L: The frequency of p53, K-ras mutations, and
microsatellite instability differs in uterine endometrioid and
serous carcinoma: Evidence of distinct molecular genetic pathways.
Cancer. 88:814–824. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kallakury BV, Ambros RA, Hayner-Buchan AM,
Sheehan CE, Malfetano JH and Ross JS: Cell proliferation-associated
proteins in endometrial carcinomas, including papillary serous and
endometrioid subtypes. Int J Gynecol Pathol. 17:320–326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Salvesen HB, Iversen OE and Akslen LA:
Identification of high-risk patients by assessment of nuclear Ki-67
expression in a prospective study of endometrial carcinomas. Clin
Cancer Res. 4:2779–2785. 1998.PubMed/NCBI
|
|
18
|
Geisler JP, Geisler HE, Miller GA, Wiemann
MC, Zhou Z and Crabtree W: MIB-1 in endometrial carcinoma:
Prognostic significance with 5-year follow-up. Gynecol Oncol.
75:432–436. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Semczuk A, Skomra D, Cybulski M and
Jakowicki JA: Immunohistochemical analysis of MIB-1 proliferative
activity in human endometrial cancer. Correlation with
clinicopathological parameters, patient outcome, retinoblastoma
immunoreactivity and K-ras codon 12 point mutations. Histochem J.
33:193–200. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lundgren C, Auer G, Frankendal B, Moberger
B, Nilsson B and Nordstrom B: Nuclear DNA content, proliferative
activity, and p53 expression related to clinical and
histopathologic features in endometrial carcinoma. Int J Gynecol
Pathol. 12:110–118. 2002. View Article : Google Scholar
|
|
21
|
AlHilli MM, Bakkum-Gamez JN, Mariani A,
Weaver AL, McGree ME, Keeney GL, Jatoi A, Dowdy SC and Podratz KC:
Risk-adjusted outcomes in elderly endometrial cancer patients:
Implications of the contrasting impact of age on progression-free
and cause-specific survival. Gynecol Oncol. 138:133–140. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fleming ND, Lentz SE, Cass I, Li AJ,
Karlan BY and Walsh CS: Is older age a poor prognostic factor in
stage I and II endometrioid endometrial adenocarcinoma? Gynecol
Oncol. 120:189–192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Farley JH, Nycum LR, Birrer MJ, Park RC
and Taylor RR: Age-specific survival of women with endometrioid
adenocarcinoma of the uterus. Gynecol Oncol. 79:86–89. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jolly S, Vargas CE, Kumar T, Weiner SA,
Brabbins DS, Chen PY, Floyd W and Martinez AA: The impact of age on
long-term outcome in patients with endometrial cancer treated with
postoperative radiation. Gynecol Oncol. 103:87–93. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vance S, Yechieli R, Cogan C, Hanna R,
Munkarah A and Elshaikh MA: The prognostic significance of age in
surgically staged patients with Type II endometrial carcinoma.
Gynecol Oncol. 126:16–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Connelly PJ, Alberhasky RC and
Christopherson WM: Carcinoma of the endometrium. III. Analysis of
865 cases of adenocarcinoma and adenoacanthoma. Obstet Gynecol.
59:569–575. 1982.PubMed/NCBI
|
|
27
|
Goff BA, Kato D, Schmidt RA, Ek M, Ferry
JA, Muntz HG, Cain JM, Tamimi HK, Figge DC and Greer BE: Uterine
papillary serous carcinoma: Patterns of metastatic spread. Gynecol
Oncol. 54:264–268. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lax SF, Pizer ES, Ronnett BM and Kurman
RJ: Clear cell carcinoma of the endometrium is characterized by a
distinctive profile of p53, Ki-67, estrogen, and progesterone
receptor expression. Hum Pathol. 29:551–558. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jia L, Yuan Z, Wang Y, Cragun JM, Kong B
and Zheng W: Primary sources of pelvic serous cancer in patients
with endometrial intraepithelial carcinoma. Modern pathology : An
official journal of the United States and Canadian Academy of
Pathology. Inc. 28:118–127. 2015.
|
|
30
|
Creasman W: Revised FIGO staging for
carcinoma of the endometrium. Int J Gynaecol Obstet. 105:1092009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zaino RJ, Kurman RJ, Diana KL and Morrow
CP: The utility of the revised International Federation of
Gynecology and Obstetrics histologic grading of endometrial
adenocarcinoma using a defined nuclear grading system. A
Gynecologic Oncology Group study. Cancer. 75:81–86. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fukuda K, Mori M, Uchiyama M, Iwai K,
Iwasaka T and Sugimori H: Prognostic significance of progesterone
receptor immunohistochemistry in endometrial carcinoma. Gynecol
Oncol. 69:220–225. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Matias-Guiu X, Catasus L, Bussaglia E,
Lagarda H, Garcia A, Pons C, Muñoz J, Argüelles R, Machin P and
Prat J: Molecular pathology of endometrial hyperplasia and
carcinoma. Hum Pathol. 32:569–577. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Berchuck A and Boyd J: Molecular basis of
endometrial cancer. Cancer. 76 Suppl:2034–2040. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
An HJ, Logani S, Isacson C and Ellenson
LH: Molecular characterization of uterine clear cell carcinoma.
Modern pathology : An official journal of the United States and
Canadian Academy of Pathology. Inc. 17:530–537. 2004.
|
|
36
|
Huvila J, Laajala TD, Edqvist PH,
Mardinoglu A, Talve L, Pontén F, Grénman S, Carpén O, Aittokallio T
and Auranen A: Combined ASRGL1 and p53 immunohistochemistry as an
independent predictor of survival in endometrioid endometrial
carcinoma. Gynecol Oncol. 149:173–180. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Obata T, Nakamura M, Mizumoto Y, Iizuka T,
Ono M, Terakawa J, Daikoku T and Fujiwara H: Dual expression of
immunoreactive estrogen receptor β and p53 is a potential predictor
of regional lymph node metastasis and postoperative recurrence in
endometrial endometrioid carcinoma. PLoS One. 12:e01886412017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Geels YP, van der Putten LJ, van Tilborg
AA, Lurkin I, Zwarthoff EC, Pijnenborg JM, van den Berg-van Erp SH,
Snijders MP, Bulten J, Visscher DW, et al: Immunohistochemical and
genetic profiles of endometrioid endometrial carcinoma arising from
atrophic endometrium. Gynecol Oncol. 137:245–251. 2015. View Article : Google Scholar : PubMed/NCBI
|
